Literature DB >> 11228531

Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models.

S Carlin1, S H Cunningham, M Boyd, A G McCluskey, R J Mairs.   

Abstract

To evaluate the potential of the expression of the sodium/iodide symporter (NIS) as a means of targeting radioiodine to tumor cells, we have employed plasmid-mediated transfection of the NIS gene into a range of mammalian cell hosts. We observed perchlorate-inhibitable iodide uptake up to 41-fold over control in all NIS-transfected cells. We assessed the effect of NIS expression followed by exposure to 131I- on the clonogenic survival of UVW glioma cells. After exposure of two-dimensional monolayer cultures of UVW-NIS cells to 131I- at a radioactive concentration of 4 MBq/mL, clonogenic survival was reduced to 21%. Similar treatment of UVW-NIS cells in three-dimensional spheroid cultures resulted in a reduction of clonogenic survival to 2.5%. This increase in sensitivity to 131I- exposure is likely to be due to a radiological bystander effect. These results are very encouraging for the development of a novel cytotoxic gene-therapy strategy in which a radiological bystander effect plays a significant role in tumor cell sterilization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11228531     DOI: 10.1038/sj.cgt.7700264

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  11 in total

1.  Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.

Authors:  Sweta K Gupta; Elisa A Torrico Guzmán; Samantha A Meenach
Journal:  Int J Cancer       Date:  2017-08-18       Impact factor: 7.396

2.  Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor.

Authors:  David Dingli; Brad J Kemp; Michael K O'Connor; John C Morris; Stephen J Russell; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

3.  Noninvasive radiological imaging of pulmonary gene transfer and expression using the human sodium iodide symporter.

Authors:  Gang Niu; Kimberly J Krager; Michael M Graham; Richard D Hichwa; Frederick E Domann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

4.  Prolonged cardiac allograft survival using iodine 131 after human sodium iodide symporter gene transfer in a rat model.

Authors:  D Ricci; A A Mennander; N Miyagi; V P Rao; H D Tazelaar; K Classic; G W Byrne; S J Russell; C G A McGregor
Journal:  Transplant Proc       Date:  2010-06       Impact factor: 1.066

5.  Human sodium iodide transporter gene-mediated imaging and therapy of mouse glioma, comparison between 188Re and 131I.

Authors:  Rui Guo; Yun Xi; Min Zhang; Ying Miao; Miao Zhang; Biao Li
Journal:  Oncol Lett       Date:  2018-01-08       Impact factor: 2.967

6.  Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.

Authors:  Meike L Schipper; Christoph G U Riese; Stephan Seitz; Alexander Weber; Martin Béhé; Tino Schurrat; Nils Schramm; Boris Keil; Heiko Alfke; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

7.  Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.

Authors:  R Huang; Z Zhao; X Ma; S Li; R Gong; A Kuang
Journal:  Cancer Gene Ther       Date:  2010-10-29       Impact factor: 5.987

8.  The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

Authors:  Michael J Willhauck; Bibi-Rana Sharif Samani; Ingo Wolf; Reingard Senekowitsch-Schmidtke; Hans-Jürgen Stark; Geerd J Meyer; Wolfram H Knapp; Burkhard Göke; John C Morris; Christine Spitzweg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-11       Impact factor: 9.236

9.  Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy.

Authors:  M A Trujillo; M J Oneal; S J McDonough; J C Morris
Journal:  Gene Ther       Date:  2012-09-13       Impact factor: 5.250

10.  Targeting Radiotherapy to Cancer by Gene Transfer.

Authors:  R. J. Mairs; M. Boyd
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.